Equities
  • Price (USD)210.10
  • Today's Change5.67 / 2.77%
  • Shares traded3.43m
  • 1 Year change-17.77%
  • Beta2.0752
Data delayed at least 15 minutes, as of Nov 20 2018 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.

  • Revenue in USD (TTM)1.85bn
  • Net income in USD372.21m
  • Incorporated1997
  • Employees8.72k
  • Location
    Align Technology Inc2820 Orchard PkwySAN JOSE 95134-2019United StatesUSA
  • Phone+1 (408) 470-1000
  • Fax+1 (408) 470-1010
  • Websitehttp://www.aligntech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Steris PLC2.70bn296.91m9.78bn12.00k33.353.1420.383.633.473.6931.5036.900.53166.895.73224,632.705.874.286.354.7341.7440.5611.056.942.018.530.288647.970.277111.77147.3511.2013.6110.33
Varian Medical Systems, Inc.2.92bn357.70m10.56bn6.60k29.736.6734.983.623.881.6131.6517.310.89213.852.93--10.949.3320.3415.8243.6342.5912.2711.861.29182.930.00--11.45-0.162358.77-3.98----
DexCom, Inc.914.60m148.90m10.78bn2.29k72.0019.1662.0811.781.680.468510.346.330.93466.506.53399,388.7015.22-7.9618.10-10.1165.0167.4516.28-5.674.43--0.381--25.3348.38184.60--47.35--
Hologic, Inc.3.22bn-457.50m11.31bn6.23k--4.65496.153.52-1.65-0.417211.618.930.42314.255.78---6.021.97-7.662.2952.7352.70-14.225.420.95473.610.5764--5.205.24-160.56--3.23--
Teleflex Incorporated2.40bn173.97m11.64bn14.40k67.114.6430.674.843.771.4152.1654.550.40432.657.06166,796.802.935.193.185.9756.1852.287.2411.551.513.650.46226.8014.906.7110.95--1.630.00
Cooper Companies Inc2.44bn324.50m12.62bn11.80k39.193.9121.905.176.552.5349.3265.710.44261.906.87207,017.005.886.966.367.8263.6862.2013.2815.441.546.510.41561.038.758.1636.148.474.980.00
Henry Schein, Inc.13.14bn537.33m13.15bn22.00k24.764.4216.871.003.482.5685.2319.501.665.278.29597,493.107.218.2813.1013.9227.2827.844.354.800.700116.810.36840.007.696.878.387.199.73--
ABIOMED, Inc.690.25m211.89m13.50bn1.14k65.2617.0360.3119.564.594.1314.9717.610.87272.2210.50603,889.8026.7917.2829.5019.6683.2383.3430.7019.356.07--0.000.0033.3430.29156.2954.8381.50--
ResMed Inc.2.40bn473.73m14.62bn5.94k31.187.6924.586.083.292.3316.7013.340.73353.455.30404,851.2014.4513.2816.3815.6158.2059.4119.7019.481.9144.530.21846.1813.239.0932.528.11-0.090715.54
Align Technology, Inc.1.85bn372.21m16.35bn8.72k44.8313.7138.368.824.563.8422.7114.921.0210.985.00212,713.1020.8015.3129.6220.0474.5975.6920.3417.931.90--0.000.0036.4421.3466.4540.0138.55--
IDEXX Laboratories, Inc.2.17bn360.65m16.69bn7.60k47.61--37.527.694.063.7224.45-0.01851.355.378.68285,523.3022.4415.3449.5033.3655.9355.2516.6213.130.690614.181.000.0010.918.7732.4710.535.56--
Zimmer Biomet Holdings Inc7.94bn480.90m23.15bn18.20k48.361.9015.112.922.358.5838.7859.890.30641.086.15436,054.901.862.752.083.0270.8571.346.078.080.95936.000.429433.441.8211.8476.99-6.4313.265.92
Data as of Nov 20 2018. Currency figures normalised to Align Technology Inc's reporting currency: US Dollar USD

Institutional shareholders

34.03%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20187.91m9.85%
BlackRock Fund Advisorsas of 30 Sep 20183.77m4.69%
SSgA Funds Management, Inc.as of 30 Sep 20183.01m3.75%
Sands Capital Management LLCas of 30 Sep 20182.84m3.54%
Renaissance Technologies LLCas of 30 Sep 20182.78m3.46%
Polen Capital Management LLCas of 30 Sep 20182.11m2.63%
Fidelity Management & Research Co.as of 30 Sep 20181.76m2.19%
Invesco Capital Management LLCas of 30 Sep 20181.09m1.36%
Geode Capital Management LLCas of 30 Sep 20181.05m1.31%
T. Rowe Price Associates, Inc.as of 30 Sep 20181.01m1.26%
More ▼
Data from 30 Sep 2018 - 30 Sep 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.